Key result
Direct oral anticoagulants, including factor Xa and thrombin inhibitors, are reviewed for their characteristics and clinical efficacy in the prevention and treatment of venous thromboembolism.
This narrative review summarizes the characteristics and clinical evidence for direct oral anticoagulants in the prevention and treatment of venous thromboembolism.
Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral vitamin K antagonists. Recently, new oral anticoagulant drugs have been developed and licensed, including direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g. dabigatran etexilate). This narrative review focusses on the characteristics of these direct anticoagulants and the main results of published clinical studies on their use in the prevention and treatment of VTE.
No takes yet. Share an insight, caveat, or question.
Franchini et al. (2016) conducted a review in Venous thromboembolism (VTE). Direct oral anticoagulants vs. Traditional anticoagulants (parenteral heparins and oral vitamin K antagonists) was evaluated. Direct oral anticoagulants, including factor Xa and thrombin inhibitors, are reviewed for their characteristics and clinical efficacy in the prevention and treatment of venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: